Format

Send to

Choose Destination
J Thorac Oncol. 2018 Nov 23. pii: S1556-0864(18)33454-3. doi: 10.1016/j.jtho.2018.11.011. [Epub ahead of print]

Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC).

Author information

1
Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
2
Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: jgainor@partners.org.

Abstract

INTRODUCTION:

Immunotherapy has revolutionized the treatment of NSCLC, but little is known about the activity of programmed cell death 1 and programmed death ligand 1 blockade across age groups.

METHODS:

We retrospectively evaluated patients with NSCLC who initiated programmed cell death 1 and programmed death ligand 1 inhibitors from January 2013 through July 2017. Medical records and radiographic imaging were reviewed to determine progression-free survival (PFS) and overall survival (OS). We also compared immunotherapy-related toxicities, steroid use, and hospitalizations by age.

RESULTS:

Of the 245 patients, 26.1% were younger than 60 years, 31.4% were age 60 to 69 years, 31.0% were age 70 to 79 years, and 11.4% were age 80 years or older. The median PFS times by age group were as follows: younger than 60 years, 1.81 months; age 60 to 69 years, 2.53 months; age 70 to 79 years, 3.75 months; and age 80 years or older, 1.64 months (log-rank p value = 0.055). The median OS times by age group were as follows: younger than 60 years, 13.01 months; age 60 to 69 years, 14.56 months; age 70 to 79 years, 12.92 months; and age 80 years or older, 3.62 months (log-rank p value = 0.011). Rates of immunotherapy-related toxicities, steroid use, and hospitalizations did not differ by age.

CONCLUSIONS:

Although the OS and PFS benefits of immunotherapy differ by age, the rates of toxicity are similar regardless of age.

KEYWORDS:

Immunotherapy; Immunotherapy-related adverse events; Non–small cell lung cancer; Older adults

PMID:
30476576
DOI:
10.1016/j.jtho.2018.11.011

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center